Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 202 articles:
HTML format
Text format



Single Articles


    November 2018
  1. HOFMEISTER MG, Rosenthal EM, Barker LK, Rosenberg ES, et al
    Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.
    Hepatology. 2018 Nov 6. doi: 10.1002/hep.30297.
    PubMed     Text format     Abstract available


  2. DAVIS C, Mgomella GS, Filipe ADS, Frost EH, et al
    New highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments.
    Hepatology. 2018 Nov 2. doi: 10.1002/hep.30342.
    PubMed     Text format     Abstract available


  3. WANG YH, Chuang YH, Wu CF, Jan MC, et al
    Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase.
    Hepatology. 2018 Nov 1. doi: 10.1002/hep.30339.
    PubMed     Text format     Abstract available


    October 2018
  4. MUELLER H, Lopez A, Tropberger P, Wildum S, et al
    PAPD5/7 are novel host factors that are required for Hepatitis B virus RNA stabilization.
    Hepatology. 2018 Oct 26. doi: 10.1002/hep.30329.
    PubMed     Text format     Abstract available


  5. LIU S, Zhou B, Valdes JD, Sun J, et al
    Serum HBV RNA: a New Potential Biomarker for Chronic Hepatitis B Virus Infection.
    Hepatology. 2018 Oct 25. doi: 10.1002/hep.30325.
    PubMed     Text format     Abstract available


  6. CHEN Y, Hao X, Sun R, Wei H, et al
    NK cell-derived IFN-gamma promotes hepatocellular carcinoma through EpCAM-EMT axis in hepatitis B virus transgenic mice.
    Hepatology. 2018 Oct 17. doi: 10.1002/hep.30317.
    PubMed     Text format     Abstract available


  7. ROSENTHAL P, Ling SC, Belle SH, Murray KF, et al
    Combination of entecavir/ peginterferon alfa-2a in children with HBeAg-positive immune tolerant chronic hepatitis B virus infection.
    Hepatology. 2018 Oct 15. doi: 10.1002/hep.30312.
    PubMed     Text format     Abstract available


  8. PARK H, Wang W, Henry L, Nelson DR, et al
    Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S.
    Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303.
    PubMed     Text format     Abstract available


    September 2018
  9. BOESECKE C, Rockstroh JK
    (Mid)West Side Story: Acute Hepatitis C Virus Infection and the Opioid Epidemic in the United States.
    Hepatology. 2018 Sep 25. doi: 10.1002/hep.30290.
    PubMed     Text format     Abstract available


  10. YEO YH, Le MH, Chang ET, Henry L, et al
    The prevalence of undetectable vaccine-induced immunity against hepatitis B virus in US adults at high risk for infection.
    Hepatology. 2018 Sep 23. doi: 10.1002/hep.30285.
    PubMed     Text format     Abstract available


  11. ANASTASIOU OE, Widera M, Westhaus S, Timmer L, et al
    Clinical outcome and viral genome variability of hepatitis B virus induced acute liver failure (HEP-18-0579).
    Hepatology. 2018 Sep 19. doi: 10.1002/hep.30279.
    PubMed     Text format     Abstract available


  12. SONG ATW, Abdala E, de Martino RB, Malbouisson LMS, et al
    Liver transplantation for fulminant hepatitis due to yellow fever.
    Hepatology. 2018 Sep 15. doi: 10.1002/hep.30273.
    PubMed     Text format     Abstract available


  13. LIU X, Duan X, Holmes JA, Li W, et al
    A novel lncRNA regulates HCV infection through IFI6.
    Hepatology. 2018 Sep 10. doi: 10.1002/hep.30266.
    PubMed     Text format     Abstract available


  14. KIM JD, Cho EJ, Ahn C, Park SK, et al
    A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure.
    Hepatology. 2018 Sep 8. doi: 10.1002/hep.30262.
    PubMed     Text format     Abstract available


  15. WANG J, Chen J, Liu Y, Zeng X, et al
    Hepatitis B Virus Induces Autophagy to Promote its Replication by the Axis of miR-192-3p-XIAP via NF-kappaB Signaling.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30248.
    PubMed     Text format     Abstract available


  16. KAO WY, Su CW, Tan EC, Lee PC, et al
    Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B or C.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30247.
    PubMed     Text format     Abstract available


  17. NGUYEN MH, Lim JK, Ozbay AB, Fraysse J, et al
    Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B.
    Hepatology. 2018 Sep 2. doi: 10.1002/hep.30246.
    PubMed     Text format     Abstract available


    August 2018
  18. TIAN Y, Ou JJ
    HBV-specific T cells as a Biomarker for Discontinuation of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
    Hepatology. 2018 Aug 31. doi: 10.1002/hep.30243.
    PubMed     Text format     Abstract available


  19. FOURATI S, Rodriguez C, Hezode C, Soulier A, et al
    Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.
    Hepatology. 2018 Aug 19. doi: 10.1002/hep.30225.
    PubMed     Text format     Abstract available


  20. ANAND L, Choudhury A, Bihari C, Sharma BC, et al
    Flare of Autoimmune Hepatitis causing acute on chronic liver failure (ACLF): diagnosis and response to corticosteroid therapy.
    Hepatology. 2018 Aug 16. doi: 10.1002/hep.30205.
    PubMed     Text format     Abstract available


  21. HOOGEVEEN RC, Lauer GM
    Innocent spectators, helping hands or a fifth column? Acute hepatitis A infection reveals important insights into bystander T cells.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30216.
    PubMed     Text format     Abstract available


  22. RAY RB, Ray R
    Hepatitis C virus manipulates humans as its favorite host for long term relationship.
    Hepatology. 2018 Aug 13. doi: 10.1002/hep.30214.
    PubMed     Text format     Abstract available


  23. MURRAY KF, Balistreri WF, Bansal S, Whitworth S, et al
    Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123.
    PubMed     Text format     Abstract available


  24. LI CL, Li CY, Lin YY, Ho MC, et al
    Androgen Receptor Enhances Hepatic TERT Transcription after Hepatitis B Virus Integration or Point Mutation in Promoter Region.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30201.
    PubMed     Text format     Abstract available


  25. MUBARAK G, Ferstenberg R
    The efficacy of Tenofivir to prevent perinatal transmission in chronic hepatitis B mothers'. a clinical perspective.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30138.
    PubMed     Text format     Abstract available


  26. GANE EJ, Stedman CA, Schwabe C, Vijgen L, et al
    Short Duration AL-335, Odalasvir, With/Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30126.
    PubMed     Text format     Abstract available


  27. TERRAULT N, Brown R Jr, Lok A, Wong J, et al
    Preventing Perinatal Transmission of Hepatitis B Necessitates Consideration of Antiviral Treatment in Pregnancy.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30137.
    PubMed     Text format     Abstract available


  28. REFOLO G, Ciccosanti F, Di Rienzo M, Perdomo AB, et al
    Negative regulation of MAVS-mediated antiviral signaling by the mitochondrial protein LRPPRC during HCV infection.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30149.
    PubMed     Text format     Abstract available


  29. HUSSAINI T, Krajden M, Mitchell RA, Yoshida EM, et al
    Transplanting Hepatitis C seropositive, nucleic acid test negative donor organs into hepatitis C negative recipients.
    Hepatology. 2018 Aug 2. doi: 10.1002/hep.30121.
    PubMed     Text format     Abstract available


    July 2018
  30. GOLDEN-MASON L, Rosen HR
    Revisiting the Paradox of ISG expression as a predictor of HCV treatment response, a decade later.
    Hepatology. 2018 Jul 28. doi: 10.1002/hep.30195.
    PubMed     Text format     Abstract available


  31. VINIKOOR MJ, Sinkala E, Chihota B, Kanunga A, et al
    Hepatitis B therapy as HIV prevention in Africa: a case series from Zambia.
    Hepatology. 2018 Jul 18. doi: 10.1002/hep.30183.
    PubMed     Text format     Abstract available


  32. JAIN MK, Thamer M, Therapondos G, Shiffman ML, et al
    Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
    Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171.
    PubMed     Text format     Abstract available


  33. TUCCI F, Calbi V, Barzaghi F, Migliavacca M, et al
    Successful treatment with Harvoni((R)) in an ADA-SCID infant with HCV infection allowed gene therapy with Strimvelis((R)).
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30160.
    PubMed     Text format     Abstract available


  34. CHU CM, Liaw YF
    Age at HBeAg seroconversion and other factors for outcomes of chronic hepatitis B.
    Hepatology. 2018 Jul 16. doi: 10.1002/hep.30179.
    PubMed     Text format     Abstract available


    June 2018
  35. HAYASHI S, Khan A, Simons BC, Homan C, et al
    A novel association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan Native People.
    Hepatology. 2018 Jun 12. doi: 10.1002/hep.30111.
    PubMed     Text format     Abstract available


  36. MARTINS PN
    Transplantation of Livers from Viremic HCV Positive Donors into HCV Negative Recipients.
    Hepatology. 2018 Jun 11. doi: 10.1002/hep.30106.
    PubMed     Text format    


  37. QUINET J, Jamard C, Burtin M, Lemasson M, et al
    Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
    Hepatology. 2018;67:2127-2140.
    PubMed     Text format     Abstract available


    May 2018
  38. LIU N, Liu Q, Yang X, Zhang F, et al
    Hepatitis B virus-upregulated lnc-HUR1 promotes cell proliferation and tumorigenesis by blocking p53 activity.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30098.
    PubMed     Text format     Abstract available


  39. COURI T, Gupta T, Weyer G, Aronsohn A, et al
    Pay It Forward: Building Capacity to Treat Hepatitis C by Training Our Own Residents.
    Hepatology. 2018 May 23. doi: 10.1002/hep.30101.
    PubMed     Text format    


  40. SALAM KA, Wang RY, Grandinetti T, De Giorgi V, et al
    Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.
    Hepatology. 2018 May 9. doi: 10.1002/hep.30087.
    PubMed     Text format     Abstract available


  41. ZHANG H, Zhang C, Tang H, Gao S, et al
    CD2-associated Protein Contributes to Hepatitis C Virus Propagation and Steatosis by Disrupting Insulin Signaling.
    Hepatology. 2018 May 5. doi: 10.1002/hep.30073.
    PubMed     Text format     Abstract available


    April 2018
  42. ALAO H, Cam M, Keembiyehetty C, Zhang F, et al
    Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy.
    Hepatology. 2018 Apr 27. doi: 10.1002/hep.29921.
    PubMed     Text format     Abstract available


  43. LIM TY, Martinez-Llordella M, Kodela E, Gray E, et al
    Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis.
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30059.
    PubMed     Text format    


  44. YANG JD, Gores GJ
    Does Cirrhosis Associated with Well Controlled Viral Hepatitis Confer a Risk for Extrahepatic Cancer?
    Hepatology. 2018 Apr 26. doi: 10.1002/hep.30063.
    PubMed     Text format    


  45. WIRTH S, Zhang H, Hardikar W, Schwarz KB, et al
    Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children with Chronic Hepatitis B: The PEG-B-ACTIVE Study.
    Hepatology. 2018 Apr 24. doi: 10.1002/hep.30050.
    PubMed     Text format     Abstract available


  46. VERRIER ER, Yim SA, Heydmann L, El Saghire H, et al
    Hepatitis B virus evasion from cGAS sensing in human hepatocytes.
    Hepatology. 2018 Apr 20. doi: 10.1002/hep.30054.
    PubMed     Text format     Abstract available


  47. CHOLANKERIL G, Gadiparthi C, Kim D, Ahmed A, et al
    Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30043.
    PubMed     Text format    


  48. TERRAULT NA
    Hepatitis C in Patients with Renal Disease: A Deeper Dive into the KDIGO Guideline.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30047.
    PubMed     Text format    


  49. REAU N, Kwo PY, Rhee S, Brown RS Jr., et al
    Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046.
    PubMed     Text format     Abstract available


  50. CHHATWAL J, Bethea ED, Samur S, Chung RT, et al
    Reply to Expanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected Recipients.
    Hepatology. 2018 Apr 19. doi: 10.1002/hep.30042.
    PubMed     Text format    


  51. WONG LL, Fisher HF, Stocken DD, Rice S, et al
    The Impact of Autoimmune Hepatitis and its Treatment on Health Utility.
    Hepatology. 2018 Apr 17. doi: 10.1002/hep.30031.
    PubMed     Text format     Abstract available


  52. ALLAIRE M, Nahon P, Layese R, Bourcier V, et al
    Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.
    Hepatology. 2018 Apr 16. doi: 10.1002/hep.30034.
    PubMed     Text format     Abstract available


  53. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Text format     Abstract available


  54. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Text format     Abstract available


  55. PERLEMUTER G
    Circulating bugs in blood in alcoholic liver disease!
    Hepatology. 2018;67:1207-1209.
    PubMed     Text format    


    March 2018
  56. FAILLACI F, Marzi L, Critelli R, Milosa F, et al
    Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals.
    Hepatology. 2018 Mar 31. doi: 10.1002/hep.29911.
    PubMed     Text format     Abstract available


  57. GUO JT, Block TM
    Do hepatitis B surface antigens have any role in viral carcinogenesis?
    Hepatology. 2018 Mar 24. doi: 10.1002/hep.29886.
    PubMed     Text format    


  58. RAMAMURTHY N, Marchi E, Ansari MA, Pedergnana V, et al
    Impact of IFNL4 genotype on Interferon-stimulated Gene Expression during DAA therapy for Hepatitis C.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29877.
    PubMed     Text format     Abstract available


  59. NISHIDA N, Sugiyama M, Sawai H, Nishina S, et al
    Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.
    Hepatology. 2018 Mar 13. doi: 10.1002/hep.29876.
    PubMed     Text format     Abstract available


  60. VAN CAMPENHOUT MJH, van Bommel F, Pfefferkorn M, Fischer J, et al
    Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.
    Hepatology. 2018 Mar 7. doi: 10.1002/hep.29872.
    PubMed     Text format     Abstract available


    February 2018
  61. FOSTER GR, Agarwal K, Cramp ME, Moreea S, et al
    Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial.
    Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852.
    PubMed     Text format     Abstract available


  62. KWON YC, Meyer K, Peng G, Chatterjee S, et al
    Hepatitis C virus E2 envelope glycoprotein induces an immunoregulatory phenotype in macrophages.
    Hepatology. 2018 Feb 14. doi: 10.1002/hep.29843.
    PubMed     Text format     Abstract available


  63. DOI A, Hikita H, Sakamori R, Tahata Y, et al
    NS5A-P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29836.
    PubMed     Text format    


  64. SMITH D, Magri A, Bonsall D, Ip CL, et al
    Resistance analysis of genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.
    Hepatology. 2018 Feb 9. doi: 10.1002/hep.29837.
    PubMed     Text format     Abstract available


  65. TERRAULT NA, Lok AS, McMahon BJ, Chang KM, et al
    Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.
    Hepatology. 2018 Feb 5. doi: 10.1002/hep.29800.
    PubMed     Text format    


  66. ATKINSON SR, McQuillin A, Morgan MY, Thursz MR, et al
    People who survive an episode of severe alcoholic hepatitis should be advised to maintain total abstinence from alcohol.
    Hepatology. 2018 Feb 2. doi: 10.1002/hep.29825.
    PubMed     Text format    


    January 2018
  67. LAMPERTICO P, Berg T
    Less can be more - a finite treatment approach for HBeAg-negative chronic hepatitis B.
    Hepatology. 2018 Jan 30. doi: 10.1002/hep.29821.
    PubMed     Text format    


  68. BERENGUER J, Gil-Martin A, Jarrin I, Moreno A, et al
    All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29814.
    PubMed     Text format     Abstract available


  69. HORST AK, Wegscheid C, Schaefers C, Schiller B, et al
    CEACAM1 controls IL-2-dependent regulatory T cell induction in immune-mediated hepatitis.
    Hepatology. 2018 Jan 29. doi: 10.1002/hep.29812.
    PubMed     Text format     Abstract available


  70. ETZION O
    Treatment for Hepatitis Delta Virus with the Prenylation Inhibitor lonafranib: It's Getting Closer.
    Hepatology. 2018 Jan 24. doi: 10.1002/hep.29807.
    PubMed     Text format    


  71. LO GH
    Does antiplatelet therapy really reduce the risk of hepatocellular carcinoma in hepatitis B patients with antiviral drug?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29794.
    PubMed     Text format    


  72. MARTINI S, Caccamo L, Rizzetto M
    Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D?
    Hepatology. 2018 Jan 21. doi: 10.1002/hep.29796.
    PubMed     Text format    


  73. YEN CJ, Ai YL, Tsai HW, Chan SH, et al
    Hepatitis B virus surface gene pre-S2 mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection.
    Hepatology. 2018 Jan 19. doi: 10.1002/hep.29790.
    PubMed     Text format     Abstract available


  74. INOUE J, Ninomiya M, Shimosegawa T, McNiven MA, et al
    Cellular membrane trafficking machineries utilized by the hepatitis viruses.
    Hepatology. 2018 Jan 13. doi: 10.1002/hep.29785.
    PubMed     Text format     Abstract available


  75. LIN KY, Hsieh SM, Sun HY, Lo YC, et al
    Serologic Responses and Effectiveness of Hepatitis A Vaccination Among HIV-Positive Individuals During the Outbreak of Acute Hepatitis A.
    Hepatology. 2018 Jan 12. doi: 10.1002/hep.29780.
    PubMed     Text format     Abstract available


  76. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Response to Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29770.
    PubMed     Text format    


  77. CONGLY SE, Lee SS
    Treatment of Acute HCV Cost-Effective but at What Price?
    Hepatology. 2018 Jan 5. doi: 10.1002/hep.29771.
    PubMed     Text format    


  78. ZHANG H, Lian M, Zhang J, Bian Z, et al
    A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation.
    Hepatology. 2018;67:232-246.
    PubMed     Text format     Abstract available


  79. HERRMANN E, de Ledinghen V, Cassinotto C, Chu WC, et al
    Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.
    Hepatology. 2018;67:260-272.
    PubMed     Text format     Abstract available


    December 2017
  80. GRAKOUI A, Walker CM
    Of mice, rats and men: Small animal model of hepatitis C virus infection.
    Hepatology. 2017 Dec 27. doi: 10.1002/hep.29765.
    PubMed     Text format    


  81. SU TH, Tseng TC, Kao JH
    HCC risk in patients with HBV-related cirrhosis receiving NA therapy: is HCC prevented or delayed?
    Hepatology. 2017 Dec 18. doi: 10.1002/hep.29740.
    PubMed     Text format    


  82. GARCIA-TSAO G
    Regression of HCV cirrhosis: Time will tell.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29720.
    PubMed     Text format    


  83. WANG S, Wang H, Ding WX
    Pyroptosis, a Novel Player for Alcoholic Hepatitis?
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29725.
    PubMed     Text format    


  84. CHHATWAL J, Samur S, Bethea ED, Ayer T, et al
    Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.
    Hepatology. 2017 Dec 9. doi: 10.1002/hep.29723.
    PubMed     Text format     Abstract available


  85. XU C, Zhang C, Ji J, Wang C, et al
    CD36 Deficiency Attenuates Immune-Mediated Hepatitis in Mice by Modulating the Proapoptotic Effects of CXCL10.
    Hepatology. 2017 Dec 8. doi: 10.1002/hep.29716.
    PubMed     Text format     Abstract available


  86. BARI K, Luckett K, Kaiser T, Diwan T, et al
    Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29704.
    PubMed     Text format     Abstract available


  87. LI DK, Ren Y, Fierer DS, Rutledge S, et al
    The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.
    PubMed     Text format     Abstract available


  88. SORIA A, Lapadula G, Fabbiani M, Gori A, et al
    Lower effectiveness of hepatitis C antiviral treatment in patients with hepatocellular carcinoma: Is active tumor the clue?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29700.
    PubMed     Text format    


  89. WANG W, Wang Y, Qu C, Wang S, et al
    The RNA genome of hepatitis E virus robustly triggers antiviral interferon response.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29702.
    PubMed     Text format     Abstract available


  90. JI F, Yeo YH, Wei MT, Wei B, et al
    Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: does direct-acting antiviral regimens matter?
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29701.
    PubMed     Text format    


  91. GERMANIDIS G, Hytiroglou P, Vassiliadis T, Speletas M, et al
    Checkpoint modulation in chronic hepatitis B: From hypothesis to approval.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29695.
    PubMed     Text format    


  92. HARRINGTON PR, Komatsu TE, Deming DJ, Donaldson EF, et al
    Impact of Hepatitis C Virus Polymorphisms on Direct-Acting Antiviral Treatment Efficacy: Regulatory Analyses and Perspectives.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29693.
    PubMed     Text format     Abstract available


  93. ALNUAIMI K, Lavole J, Lascoux-Combes C, Afonso AR, et al
    Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
    Hepatology. 2017 Dec 1. doi: 10.1002/hep.29697.
    PubMed     Text format    


  94. CHEN X, Oidovsambuu O, Liu P, Grosely R, et al
    A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.
    Hepatology. 2017;66:1739-1749.
    PubMed     Text format     Abstract available


    November 2017
  95. SINGH AK, Rooge SB, Varshney A, Vasudevan M, et al
    Global micro RNA expression profiling in the liver biopsies of Hepatitis B Virus infected patients suggests specific miRNA signatures for viral persistence and hepatocellular injury.
    Hepatology. 2017 Nov 30. doi: 10.1002/hep.29690.
    PubMed     Text format     Abstract available


  96. SAAB S, Le L, Saggi S, Sundaram V, et al
    Towards the Elimination of Hepatitis C in the United States.
    Hepatology. 2017 Nov 27. doi: 10.1002/hep.29685.
    PubMed     Text format     Abstract available


  97. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed     Text format    


  98. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed     Text format    


  99. POORDAD F, Pol S, Asatryan A, Buti M, et al
    Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671.
    PubMed     Text format     Abstract available


  100. KALAL C, Shukla A, Mohanka R, Vora M, et al
    Sofosbuvir, Peg Interferon & Ribavirin for retreatment of HCV genotype 1b following Sofosbuvir and Ledipasvir failure.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29667.
    PubMed     Text format    


  101. YURDAYDIN C, Keskin O, Kalkan C, Karakaya F, et al
    Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The lowr HDV - 1 study.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29658.
    PubMed     Text format     Abstract available


  102. PARK H, O'Brien TR, Rehermann B
    The role of genetics in hepatic fibrosis amongst HCV patients.
    Hepatology. 2017 Nov 20. doi: 10.1002/hep.29659.
    PubMed     Text format    


  103. CHAUHAN A, Adams DH
    Exercise alters the hepatic immunophenotype to protect against inflammatory liver disease.
    Hepatology. 2017 Nov 16. doi: 10.1002/hep.29657.
    PubMed     Text format    


  104. JENG WJ, Chen YC, Chien RN, Sheen IS, et al
    Incidence and predictors of HBsAg seroclearance after cessation of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29640.
    PubMed     Text format     Abstract available


  105. KHANOVA E, Wu R, Wang W, Yan R, et al
    Pyroptosis by Caspase11/4-Gasdermin-D Pathway in Alcoholic Hepatitis.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29645.
    PubMed     Text format     Abstract available


  106. SIKAVI C, Chen PH, Lee AD, Saab EG, et al
    Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.
    Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.
    PubMed     Text format     Abstract available


    October 2017
  107. PURI P, Liangpunsakul S, Christensen JE, Shah VH, et al
    The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.
    Hepatology. 2017 Oct 30. doi: 10.1002/hep.29623.
    PubMed     Text format     Abstract available


  108. LIU J
    Hepatitis B reactivation in chronic hepatitis C patients treated with interferon or pan-oral direct-acting antivirals.
    Hepatology. 2017 Oct 28. doi: 10.1002/hep.29620.
    PubMed     Text format    


  109. SHEN F, Li Y, Yang Wang, Sozzi V, et al
    Hepatitis B Virus Sensitivity to Interferon-alpha in Hepatocytes is More Associated with Cellular Interferon Response than with Viral Genotype.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29609.
    PubMed     Text format     Abstract available


  110. STRUBLE K, Chan-Tack K, Qi K, Naeger LK, et al
    Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV genotype: FDA's Evaluation.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29601.
    PubMed     Text format     Abstract available


  111. BETHEA E, Chen Q, Hur C, Chung RT, et al
    Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611.
    PubMed     Text format     Abstract available


  112. KUSHNER T, Shinkai K, Fox L, Ying D, et al
    New Presentation of Autoimmune Hepatitis with Erythema Multiforme.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29610.
    PubMed     Text format    


  113. YOUNOSSI ZM
    The Efficacy of New Anti-Viral Regimens for Hepatitis C Infection: Evidence from A Systematic Review.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29580.
    PubMed     Text format    


  114. GONZALEZ SA, Trotter JF
    The Rise of the Opioid Epidemic and Hepatitis C Positive Organs: A New Era in Liver Transplantation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29572.
    PubMed     Text format     Abstract available


  115. BIAN Y, Zhang Z, Sun Z, Zhao J, et al
    Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.
    Hepatology. 2017;66:1067-1082.
    PubMed     Text format     Abstract available


  116. CAO Z, Liu Y, Ma L, Lu J, et al
    A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.
    Hepatology. 2017;66:1058-1066.
    PubMed     Text format     Abstract available


    September 2017
  117. KAMILI S, Drobeniuc J, Mixson-Hayden T, Kodani M, et al
    Delta Hepatitis: Towards Improved Diagnostics.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29564.
    PubMed     Text format    


  118. NIMGAONKAR I, Ploss A
    A porcine model for chronic hepatitis E.
    Hepatology. 2017 Sep 29. doi: 10.1002/hep.29566.
    PubMed     Text format    


  119. MAUGE L, Pavie J, Batisse D, Darnige L, et al
    Acquired hemophilia A resolution in an HCV/HIV coinfected patient with cure of hepatitis C by direct antiviral agents.
    Hepatology. 2017 Sep 28. doi: 10.1002/hep.29560.
    PubMed     Text format    


  120. CHTIOUI H
    OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29556.
    PubMed     Text format    


  121. AHMED A, Beckerman R, Younossi ZM
    Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29555.
    PubMed     Text format    


  122. MAURO E, Crespo G, Montironi C, Londono MC, et al
    Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C.
    Hepatology. 2017 Sep 27. doi: 10.1002/hep.29557.
    PubMed     Text format     Abstract available


  123. PHILIPS CA, Augustine P
    Plasma biomarkers to diagnose alcoholic hepatitis - are we there yet?
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29547.
    PubMed     Text format    


  124. YARTEL AK, Rein DB, Ann Brown K, Krauskopf K, et al
    Hepatitis C Virus Testing for Case Identification in Persons Born during 1945-1965: Results from Three Randomized Controlled Trials.
    Hepatology. 2017 Sep 23. doi: 10.1002/hep.29548.
    PubMed     Text format     Abstract available


  125. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Text format     Abstract available


  126. VIONNET J, Pascual M, Testoni B, Combet C, et al
    Late hepatitis B reactivation following DAA-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29528.
    PubMed     Text format    


  127. LEE MH, Huang YH, Chen HY, Khor CS, et al
    Human Leukocyte Antigen Variants and Risk of Hepatocellular Carcinoma Modified by HCV Genotypes: A Genome-wide Association Study.
    Hepatology. 2017 Sep 16. doi: 10.1002/hep.29531.
    PubMed     Text format     Abstract available


  128. ALTER H, Block TM, Brown N, Brownstein A, et al
    A Research Agenda for Curing Chronic Hepatitis B Virus Infection.
    Hepatology. 2017 Sep 6. doi: 10.1002/hep.29509.
    PubMed     Text format    


  129. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed     Text format    


  130. PARK H, Chen C, Wang W, Henry L, et al
    Chronic Hepatitis C Increases the Risk of Chronic Kidney Disease (CKD) while Effective HCV Treatment Decreases the Incidence of CKD.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29505.
    PubMed     Text format     Abstract available


  131. TOYODA H, Chayama K, Suzuki F, Sato K, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.
    Hepatology. 2017 Sep 2. doi: 10.1002/hep.29510.
    PubMed     Text format     Abstract available


    August 2017
  132. MANATSATHIT W, Samant H, Nakayuenyongsuk W
    Mesenchymal stem cells for hepatitis B patients with acute on chronic liver failure-Are we there?
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29493.
    PubMed     Text format    


  133. TRIVEDI S, Murthy S, Sharma H, Hartlage AS, et al
    Viral persistence, liver disease and host response in Hepatitis C-like virus rat model.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29494.
    PubMed     Text format     Abstract available


  134. PAPATHEODORIDIS GV, Manolakopoulos S, Su TH, Siakavellas S, et al
    Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.
    Hepatology. 2017 Aug 31. doi: 10.1002/hep.29497.
    PubMed     Text format     Abstract available


  135. MATTINGLY TJ 2ND, Perfetto EM, Johnson S
    Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.
    Hepatology. 2017 Aug 23. doi: 10.1002/hep.29482.
    PubMed     Text format     Abstract available


  136. HONG X, Kim ES, Guo H
    Epigenetic Regulation of Hepatitis B Virus Covalently Closed Circular DNA: Implications for Epigenetic Therapy against Chronic Hepatitis B.
    Hepatology. 2017 Aug 18. doi: 10.1002/hep.29479.
    PubMed     Text format     Abstract available


  137. HALGAND B, Desterke C, Riviere L, Fallot G, et al
    Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: A nosological and prognostic determinant.
    Hepatology. 2017 Aug 12. doi: 10.1002/hep.29463.
    PubMed     Text format     Abstract available


  138. INNES H, McAuley A, Alavi M, Valerio H, et al
    The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study.
    Hepatology. 2017 Aug 4. doi: 10.1002/hep.29419.
    PubMed     Text format     Abstract available


  139. KRISS M, Burchill M
    HCV and non-hepatic malignancy: Is pre-emptive DAA therapy indicated prior to treatment?
    Hepatology. 2017 Aug 2. doi: 10.1002/hep.29414.
    PubMed     Text format    


  140. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    Hepatology. 2017 Aug 1. doi: 10.1002/hep.29323.
    PubMed     Text format     Abstract available


    July 2017
  141. COBB DA, Golden-Mason L, Rosen HR, Hahn YS, et al
    Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29409.
    PubMed     Text format     Abstract available


  142. LI G, Zhu Y, Shao D, Chang H, et al
    Recombinant cccDNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model.
    Hepatology. 2017 Jul 27. doi: 10.1002/hep.29406.
    PubMed     Text format     Abstract available


  143. KONDILI LA, Romano F, Rolli FR, Ruggeri M, et al
    Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29399.
    PubMed     Text format     Abstract available


  144. LUCEY MR
    Redefining successful treatment of severe alcoholic hepatitis.
    Hepatology. 2017 Jul 24. doi: 10.1002/hep.29398.
    PubMed     Text format    


  145. ROSEN HR, Ghany M, Chung R, Lok A, et al
    NAM 2017 Report: A National Plan To Eliminate Hepatitis B and C In the United States By 2030 And The AASLD's Response.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29361.
    PubMed     Text format    


  146. KONERMAN MA, Thomson M, Gray K, Moore M, et al
    Impact of an Electronic Health Record Alert in Primary Care on Increasing Hepatitis C Screening and Curative Treatment for Baby Boomers.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29362.
    PubMed     Text format     Abstract available


  147. PERSICO M, Aglitti A, Caruso R, De Renzo A, et al
    Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29364.
    PubMed     Text format     Abstract available


  148. LOK AS, Chung RT, Vargas HE, Kim AY, et al
    Comments on Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Hepatology. 2017 Jul 16. doi: 10.1002/hep.29366.
    PubMed     Text format    


  149. HUANG YH, Lee SD
    Is antibody to surface antigen associated with hepatitis B reactivation in patients with resolved hepatitis B?
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29357.
    PubMed     Text format    


  150. WYLES D, Wedemeyer H, Ben-Ari Z, Gane EJ, et al
    Grazoprevir, Ruzasvir, and Uprifosbuvir for HCV After NS5A Treatment Failure.
    Hepatology. 2017 Jul 7. doi: 10.1002/hep.29358.
    PubMed     Text format     Abstract available


  151. SIMONETTO DA, Kamath PS, Shah VH
    Alcoholic Hepatitis: Continued drinking and the mourning after.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29349.
    PubMed     Text format    


  152. LIN BL, Chen JF, Qiu WH, Wang KW, et al
    Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.
    Hepatology. 2017;66:209-219.
    PubMed     Text format     Abstract available


    June 2017
  153. CHENG X, Xia Y, Serti E, Block PD, et al
    Hepatitis B virus evades innate immunity of hepatocytes but activates macrophages during infection.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.
    PubMed     Text format     Abstract available


  154. SASAKI R, Devhare P, Ray RB, Ray R, et al
    Hepatitis C virus induced tumor initiating cancer stem-like cells activate stromal fibroblasts in xenograft tumor model.
    Hepatology. 2017 Jun 30. doi: 10.1002/hep.29346.
    PubMed     Text format     Abstract available


  155. TORRES HA, Hosry J, Mahale P, Economides MP, et al
    Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29344.
    PubMed     Text format     Abstract available


  156. SISE M
    Kidney transplant recipients with Hepatitis C virus experienced 100% SVR12 rate when treated with sofosbuvir-ledipasvir.
    Hepatology. 2017 Jun 26. doi: 10.1002/hep.29339.
    PubMed     Text format    


  157. ALTAMIRANO J, Lopez-Pelayo H, Michelena J, Jones PD, et al
    Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29338.
    PubMed     Text format     Abstract available


  158. CHOI J, Han S, Kim N, Lim YS, et al
    Increasing Burden of Liver Cancer Despite Extensive Use of Antiviral Agents in a Hepatitis B Virus-Endemic Population.
    Hepatology. 2017 Jun 19. doi: 10.1002/hep.29321.
    PubMed     Text format     Abstract available


  159. PAPATHEODORIDIS GV, Idilman R, Dalekos GN, Buti M, et al
    The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29320.
    PubMed     Text format     Abstract available


  160. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Text format     Abstract available


  161. LEE M, Chung GE, Lee JH, Oh S, et al
    Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.
    Hepatology. 2017 Jun 15. doi: 10.1002/hep.29318.
    PubMed     Text format     Abstract available


  162. FALADE-NWULIA O, Sutcliffe C, Moon J, Chander G, et al
    High Hepatitis C cure rates among black and non-black HIV-infected adults in an urban center.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29308.
    PubMed     Text format     Abstract available


  163. GAO Y, Feng J, Yang G, Zhang S, et al
    HBx-elevated MSL2 Modulates HBV cccDNA through Inducing Degradation of APOBEC3B to Enhance Hepatocarcinogenesis.
    Hepatology. 2017 Jun 13. doi: 10.1002/hep.29316.
    PubMed     Text format     Abstract available


  164. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Text format     Abstract available


  165. CHHATWAL J, Samur S, Bethea E, Chung RT, et al
    Response to Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29299.
    PubMed     Text format    


  166. CHOLANKERIL G, Wong RJ, Kim D, Ahmed A, et al
    Optimal Timing for Hepatitis C Antiviral Therapy in the Peri-Transplant Period?
    Hepatology. 2017 Jun 6. doi: 10.1002/hep.29300.
    PubMed     Text format    


    May 2017
  167. GANE E
    Is HBIG still needed after liver transplantation for CHB?
    Hepatology. 2017 May 26. doi: 10.1002/hep.29292.
    PubMed     Text format    


  168. WIRTH S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, et al
    Sofosbuvir and Ribavirin in Adolescents 12 to 17 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29278.
    PubMed     Text format     Abstract available


  169. SAXENA V, Khungar V, Verna EC, Levitsky J, et al
    Safety and Efficacy of Current DAA Regimens in Kidney and Liver Transplant Recipients with Hepatitis C: Results from the HCV-TARGET Study.
    Hepatology. 2017 May 15. doi: 10.1002/hep.29258.
    PubMed     Text format     Abstract available


  170. GANE EJ, Shiffman ML, Etzkorn K, Morelli G, et al
    Sofosbuvir-velpatasvir with ribavirin for 24 weeks in HCV patients previously treated with a direct-acting antiviral regimen.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29256.
    PubMed     Text format     Abstract available


  171. WANG CC, Kao JH
    Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Hepatology. 2017 May 8. doi: 10.1002/hep.29252.
    PubMed     Text format    


  172. MAILLY L, Zeisel MB, Baumert TF
    Towards novel immunocompetent animal models for hepatitis B virus infection.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29249.
    PubMed     Text format    


  173. LI W, Amet T, Xing Y, Yang D, et al
    Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study.
    Hepatology. 2017 May 2. doi: 10.1002/hep.29242.
    PubMed     Text format     Abstract available


  174. REN YD, Ye ZS, Yang LZ, Jin LX, et al
    Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy.
    Hepatology. 2017;65:1765-1768.
    PubMed     Text format    


    April 2017
  175. LOUVET A, Labreuche J, Artru F, Bouthors A, et al
    Main drivers of outcome differ between short and long-term in severe alcoholic hepatitis: A prospective study.
    Hepatology. 2017 Apr 29. doi: 10.1002/hep.29240.
    PubMed     Text format     Abstract available


  176. DIAB AM, Foca A, Fusil F, Lahlali T, et al
    Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication.
    Hepatology. 2017 Apr 26. doi: 10.1002/hep.29236.
    PubMed     Text format     Abstract available


  177. MIN AD
    Low-level viremia in hepatitis B patients on antiviral treatment: Can we ignore it?
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29235.
    PubMed     Text format    


  178. BARGE S, Ziol M, Nault JC
    Autoimmune-like chronic hepatitis induced by olmesartan.
    Hepatology. 2017 Apr 24. doi: 10.1002/hep.29228.
    PubMed     Text format     Abstract available


  179. PEMBROKE T, Sebastiani G
    Hepatic steatosis, hepatitis C and human immunodeficiency viruses: A complex interplay.
    Hepatology. 2017 Apr 19. doi: 10.1002/hep.29218.
    PubMed     Text format    


  180. GUO X, Wang S, Qiu ZG, Dou YL, et al
    Efficient replication of blood borne Hepatitis C Virus in human fetal liver stem cells.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29211.
    PubMed     Text format     Abstract available


  181. ONO A, Goossens N, Finn RS, Schmidt WN, et al
    Persisting risk of hepatocellular carcinoma after HCV cure monitored by a liver transcriptome signature.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29203.
    PubMed     Text format    


  182. MERLI M, Frigeni M, Gotti M, Grossi P, et al
    Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas.
    Hepatology. 2017 Apr 5. doi: 10.1002/hep.29198.
    PubMed     Text format    


  183. CHANG ML, Liaw YF
    Overt acute hepatitis B is more severe in female patients.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29196.
    PubMed     Text format    


  184. LAI TS, Lee MH, Yang HI, You SL, et al
    Hepatitis C Viral Load, Genotype, and Increased Risk of Developing End-stage Renal Disease: REVEAL-HCV Study.
    Hepatology. 2017 Apr 2. doi: 10.1002/hep.29192.
    PubMed     Text format     Abstract available


  185. FORREST E
    Clinical Criteria are Critical to Diagnosing Alcoholic Hepatitis.
    Hepatology. 2017 Apr 1. doi: 10.1002/hep.29188.
    PubMed     Text format    


    March 2017
  186. FUNG J, Wong T, Chok K, Chan A, et al
    Long Term Outcomes of Entecavir Monotherapy for Chronic Hepatitis B after Liver Transplantation: Results up to 8 years.
    Hepatology. 2017 Mar 31. doi: 10.1002/hep.29191.
    PubMed     Text format     Abstract available


  187. LIM YS, Lee YS, Gwak GY, Byun KS, et al
    Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29187.
    PubMed     Text format     Abstract available


  188. PERRILLO RP
    HBV Reactivation During DAA Treatment of Chronic Hepatitis C: A Hidden Danger of an Otherwise Major Success Story.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29185.
    PubMed     Text format    


  189. SORIA A, Fabbiani M, Lapadula G, Gori A, et al
    Unexpected viral relapses in HCV-infected patients diagnosed with hepatocellular carcinoma during treatment with DAAs.
    Hepatology. 2017 Mar 30. doi: 10.1002/hep.29181.
    PubMed     Text format    


  190. KIM SJ, Jang JY, Kim EJ, Cho EK, et al
    Ginsenoside Rg3 Restores Hepatitis C Virus-Induced Aberrant Mitochondrial Dynamics and Inhibits Virus Propagation.
    Hepatology. 2017 Mar 22. doi: 10.1002/hep.29177.
    PubMed     Text format     Abstract available


  191. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  192. SURAWEERA D, Saab S
    Hepatitis C Treatment Threshold in Patients with Decompensated Liver Disease.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29175.
    PubMed     Text format    


  193. SASAKI R, Devhare PB, Steele R, Ray R, et al
    Hepatitis C virus induced CCL5 secretion from macrophages activates hepatic stellate cells.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29170.
    PubMed     Text format     Abstract available


  194. AHMED A, Gonzalez SA, Cholankeril G, Perumpail RB, et al
    Treatment of Patients Waitlisted for Liver Transplant with an All-Oral DAAs is a Cost-Effective Treatment Strategy in the United States.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29137.
    PubMed     Text format     Abstract available


    February 2017
  195. GOLDEN-MASON L, Rosen HR
    Galectin-9: Diverse Roles in Hepatic Immune Homeostasis and Inflammation.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29106.
    PubMed     Text format     Abstract available


  196. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Text format     Abstract available


    January 2017
  197. STEINMETZ C, Kashyap A, Zhivkova N, Alizor H, et al
    Activation of SIRT1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.
    Hepatology. 2017 Jan 21. doi: 10.1002/hep.29072.
    PubMed     Text format     Abstract available


  198. BAECHLEIN C, Becher P
    No evidence for zoonotic hepatitis E virus infection through dairy milk in Germany.
    Hepatology. 2017;65:394-395.
    PubMed     Text format    


    December 2016
  199. AYUBI E, Safiri S, Sani M, Doosti-Irani A, et al
    Effect of Metabolic syndrome on cardiovascular, hepatic events and death in CHB patients: Methodological issues.
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.29001.
    PubMed     Text format    


    November 2016
  200. FLEMMING JA, Kim WR, Brosgart CL, Terrault NA, et al
    Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28923.
    PubMed     Text format     Abstract available


  201. KIM JH, Sinn DH, Kang W, Gwak GY, et al
    Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28916.
    PubMed     Text format     Abstract available


    October 2016
  202. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: